Cargando...
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Despite impressive clinical benefit obtained with anti‐HER2‐targeted therapies, in advances stages, especially in the metastatic setting, HER2‐positive tumors remain incurable. Therefore, it is important to develop novel strategies to fight these tumors, especially when they become resistant to avai...
Gardado en:
| Publicado en: | EMBO Mol Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7207167/ https://ncbi.nlm.nih.gov/pubmed/32329582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201911498 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|